Internationally, vaccines are one of the fastest growing sectors in the pharmaceutical and biotechnology industry. This project seeks to create a streamlined pathway for Australian vaccine development from the time of conception at the laboratory bench, typically in a University research lab, all the way through to human trials and commercialisation.
Whilst Australia has an exemplary record of basic immunology and vaccine research, there has been a major failure to capture the commercial value of this Australian research. This project will landscape the vaccine space, developing a free-to-use, publicly accessible database of all interested parties in the sector, and draw them together for the first Australian Vaccine conference in December 2017.
Outcomes: A better connected Australian vaccine community, engaging through events and in person. Ten events have been held with over 350 attendees. Two products have been developed. One product was successful in winning a Biomedical Translation Bridge (BTB) grant.
|Consortium lead||Vaxine Pty Ltd|
|Consortium members||Mylexa Pty Ltd, Australian Respiratory and Sleep Medicine Institute Ltd|
|Project duration||March 2017 - May 2018 (Finished)|
|Contact||Sharen Pringle, Vaxine - firstname.lastname@example.org|
Listen to Vaxine's Professor Nikolai Petrovsky on the quest for a COVID-19 vaccine